Can a patient who has stopped Spravato (esketamine) treatment for more than 60 days restart with 84 mg twice‑weekly dosing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Restarting Spravato After >60 Days: Dosing Recommendations

No, a patient who has stopped Spravato for more than 60 days should NOT resume at 84 mg twice weekly—they must restart with the standard induction dosing protocol beginning at 56 mg. The FDA label does not provide specific guidance for treatment interruptions exceeding 60 days, but the absence of safety data for restarting at maintenance doses after prolonged discontinuation necessitates a conservative approach 1.

Dosing Algorithm After Treatment Interruption

For Interruptions >60 Days:

  • Restart as if treatment-naive: Begin with 56 mg twice weekly during a 4-week induction phase
  • Titration: May increase to 84 mg starting with the second dose based on efficacy and tolerability
  • Rationale: The FDA label establishes twice-weekly 56-84 mg dosing for initial treatment, with no provisions for abbreviated re-induction after extended gaps 1

Clinical Context from Trials:

The pivotal studies that established Spravato's efficacy used a structured induction approach with twice-weekly dosing for 4 weeks before transitioning to maintenance schedules 1. In the long-term maintenance study (Study 2), patients who achieved stable remission or response continued treatment without interruption—there were no protocols for restarting after prolonged discontinuation 1.

Key Safety Considerations

Adverse event profile is highest during initial treatment: The most common adverse events (dissociation, dizziness, nausea, vertigo) occur with greatest frequency during week 1 of treatment (16.7-20.6% incidence) and decrease substantially with ongoing treatment 2. After a 60+ day gap, the patient's tolerance may have reset, making them vulnerable to these acute effects at higher doses.

Risk mitigation:

  • Most adverse events are dose-dependent, with 84 mg showing higher rates than 56 mg 3
  • Starting at 56 mg allows assessment of current tolerability before escalation
  • The 2-hour post-dose monitoring requirement applies regardless of prior treatment history 1

Common Pitfalls to Avoid

  1. Assuming prior tolerance persists: A >60 day gap likely eliminates any pharmacologic tolerance developed during previous treatment
  2. Skipping induction: The maintenance dosing schedules (weekly or every-other-week) studied in trials were only for patients who completed induction and achieved response 1
  3. Inadequate monitoring: Even "experienced" patients require full post-dose observation when restarting after extended interruption

Practical Implementation

  • Document the treatment gap duration and reason for discontinuation
  • Obtain updated psychiatric assessment before restarting
  • Ensure the patient restarts or continues a concurrent oral antidepressant (required per FDA indication) 1
  • Follow standard induction protocol: 56 mg twice weekly, with potential increase to 84 mg from dose 2 onward based on clinical response
  • Maintain twice-weekly dosing for minimum 4 weeks before considering transition to less frequent maintenance dosing

The absence of specific FDA guidance for long interruptions mandates treating the restart as a new treatment episode to ensure patient safety.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.